

From: [Giordano, Erica](#)
To: [Patel, Manisha \(manisha.patel@novartis.com\)](#)
Cc: [Riggins, Cindy](#); [narin.ahmed@novartis.com](#)
Subject: BL 125646 Clinical Information Request
Date: Sunday, August 06, 2017 8:26:09 PM
Attachments: [image001.png](#)


Please see the information request below and provide a response by 4 pm on August 7, 2017. Please send a response directly to this e-mail and follow-up by submitting the information as an official amendment to the BLA.

For the subjects below please provide the following information:

1. Wbc on the day of the start of lymphodepletion
2. Type and dates of lymphodepletion, if not given, please provide the reason

Subjects:

(b) (6)

A large rectangular gray box redacting the subject information.

Please confirm receipt of this request.

Thank you,

Erica Giordano

Regulatory Project Manager

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

Erica.Giordano@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."